Cost-effectiveness of de-escalated molecular subtype dependent use of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer in a Swedish setting
Molecular subtype-based treatment of MIBC, i.e., refraining from administering NAC to patients with Ba/Sq tumors, is cost-effective compared to the current treatment practices in Sweden.
Authors
- Lars Holmberg (ORCID: https://orcid.org/0000-0003-4417-7396)
- Fredrik Liedberg (ORCID: https://orcid.org/0000-0001-8193-0370)
- Ulf‐G. Gerdtham (ORCID: https://orcid.org/0000-0002-0647-7817)
- James W.F. Catto (ORCID: https://orcid.org/0000-0003-2787-8828)
- Sanjib Saha (ORCID: https://orcid.org/0000-0001-8649-0773)
- Christel Häggström (ORCID: https://orcid.org/0000-0001-6808-4405)
- Gottfrid Sjödahl (ORCID: https://orcid.org/0000-0002-7869-0473)
- John D. Kelly (ORCID: https://orcid.org/0000-0002-7036-1923)
- Anders Ullén (ORCID: https://orcid.org/0000-0002-9023-3259)
Institutions
- Uppsala University (SE)
- Karolinska University Hospital (SE)
- King's College London (GB)
- Lund University (SE)
- Karolinska Institutet (SE)
- Skåne University Hospital (SE)
- University College London (GB)
- University of Sheffield (GB)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-04-02
- DOI
- https://doi.org/10.3389/fonc.2025.1556881
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Skåne County Council's Research and Development Foundation
- Cancerfonden
- Fondation pour la Recherche Médicale
- Vetenskapsrådet
- Forskningsrådet om Hälsa, Arbetsliv och Välfärd
- Skånes universitetssjukhus